atr

ATR-IN-21, also known as compound 60, is a potent inhibitor of ATR, exhibiting an IC50 of less than 1000 nM [1].

ATR-IN-22 (Compound 34), an orally active ATR inhibitor, exhibits potent anti-proliferative effects on MIAPaCa-2 cells with an IC50 value of less than 1 μM and demonstrates anti-tumor activity in colon cancer [1].

ATR-IN-9 is a highly effective inhibitor of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR). With an IC50 value as low as 10 nM, ATR-IN-9 demonstrates exceptional potency.

ATR-IN-20, a potent ATM/ATR inhibitor, showcases an IC50 value of 3 nM. It also exhibits inhibitory activity against mTOR with an IC50 of 18 nM, while maintaining selectivity over PI3Kα (100 nM), ATM (100 nM), and DNA-PK (662 nM). Additionally, ATR-IN-20 has an excellent pharmacokinetic profile with an oral bioavailability (F) of 30%, and demonstrates anticancer effects.

ATR-IN-18 is an orally active ATR kinase inhibitor (IC50: 0.69 nM). aTR-IN-18 exhibited anti-proliferative effects in LoVo cells (IC50: 37.34 nM). aTR-IN-18 showed anti-tumor effects.

ATR-IN-11 (Compound Hit01) is a potent inhibitor of ataxia capillaris and Rad3-related (ATR) kinases. As a promising lead compound for developing drugs targeting the ATR kinase, a key regulatory protein in the DNA damage response (DDR) that senses replication stress (RS), ATR-IN-11 has significant potential for cancer research.

ATR-IN-16 (compound 46) is a potent ATR kinase inhibitor with significant anticancer activity in LoVo cells, as evidenced by an IC50 value of 410 nM [1].

ATR-IN-19 (Compound 15 R-configure) is an ATR inhibitor [1].

ATR-IN-7 is a potent inhibitor of ATR. This compound selectively targets ATR kinase activity, demonstrating high efficacy in disrupting ATR-related cellular processes.

ATR-IN-5 is a potent inhibitor of ATR, a member of the PIKK family of proteins involved in genome stability and DNA damage repair, with potential for treating ATR kinase-mediated diseases such as proliferative diseases and cancer.

ATR-IN-10 is a potent and highly selective inhibitor of ATR kinase (IC50: 2.978 μM).

ATR-IN-12 (Compound 5g) is a potent inhibitor of ataxia-capillaris and Rad3-related (ATR) kinase with an IC50 of 0.007 μM, making it a promising lead compound for further drug discovery studies on ATR kinases.

ATR-IN-4, a potent inhibitor of ATR (Ataxia telangiectasia mutated gene Rad 3-associated kinase), restricts the growth of DU145 prostate cancer cells and NCI-H460 lung cancer cells, with IC 50 values of 130.9 nM and 41.33 nM, respectively.

ATR-IN-13 is a potent inhibitor of ATR kinases (IC50: 2 nM) and can be used to study ATR kinase-mediated diseases (e.g. proliferative diseases, cancer).

ATR-IN-15 (compound 1) is a highly potent, orally active ATR kinase inhibitor with an IC50 of 8 nM. It also exhibits inhibitory activity against human colon tumor cells LoVo, DNA-PK, and PI3K, with IC50 values of 47, 663, and 5131 nM, respectively [1].

ATR-IN-29, a potent, orally active inhibitor of ATR kinase, exhibits an IC50 of 1 nM and demonstrates antiproliferative activity [1].

ATR-IN-23 (Compound 34), a potent and selective ATR inhibitor, exhibits an IC50 of 1.5 nM, has demonstrated antiproliferative effects on LoVo cells, and induces synthetic lethality in HT-29 cells, suggesting its utility in researching DNA damage response (DDR)-deficient cancers [1].

ATR-IN-17 is a potent inhibitor of ATR kinase with good anti-cancer effects in LoVo cells (IC50: 1 nM).

ATR-IN-8 is a potent inhibitor of ATR that has demonstrated significant research potential in cancer diseases.

ATR-IN-14 (compound 1) is a powerful ATR kinase inhibitor that significantly inhibits ATR signaling pathways following CHKI protein phosphorylation, with a remarkable inhibition rate of 98.03% at 25 nM. ATR-IN-14 also exhibits notable anticancer efficacy in LoVo cells, displaying an IC50 value of 64 nM [1].

ATR-IN-24 (Compound 1) is an ATR inhibitor exhibiting anticancer activity [1].

ATR-IN-6 is a potent inhibitor of ATR, a protein kinase involved in genome stability and DNA damage repair and a member of the PIKK family. ATR-IN-6 has shown potential for ATR kinase-mediated diseases, such as proliferative diseases and cancer.

Camonsertib (RP-3500) is a selective, orally active ATR kinase inhibitor (ATRi) with an IC50: 1.00 nM in biochemical assays and exhibits potent antitumour effects. Camonsertib is 30 times more selective for ATR than mTOR (IC50: 120 nM) and is a more active inhibitor of ATM, DNA-PK and PI3Kα kinases. PK and PI3Kα kinases.

ATR inhibitor 2 is an orally active, ATP-competitive, and selective ATR inhibitor (Ki <150 pM) with antitumor activity. ATR inhibitor 2 potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation (IC50: 8 nM).

VE-821 (ATR Inhibitor IV) is a selective ATP competitive inhibitor of ATR( Ki IC50: 13 26 nM in cell-free assays).

Flovagatran (TGN 255) is an orally active, potent, and selective inhibitor of thrombin and parenteral direct factor II.Flovagatran is used to study venous thromboembolism.

PF-07321332 is a potent and orally active inhibitor of SARS-CoV 3C-like protease (3CLPRO) .

Melagatran, a direct and orally active thrombin inhibitor, specifically inhibits thrombin without affecting other enzymes in the coagulation cascade or fibrinolytic enzymes. It does not rely on endogenous co-factors to exert its antithrombin effect, and may alleviate the harmful effects of endotoxemia. As a result, Melagatran offers a promising strategy for the prevention of arterial occlusion.

Homoveratronitrile is an impurity of Verapamil. It is also an intermediate in the preparation of the muscle relaxant Papverine.

Diatrizoic Acid (Amidotrizoic acid) is an organic, iodinated radiopaque X-ray contrast medium used in diagnostic radiography.

Tiratricol (3,3',5-Triiodothyroacetic acid) is a metabolite of T3 and T4 thyroid hormones; promoted for hyperlipidemia, localized lipodystrophy, and obesity. Tiratricol has been used in trials studying the treatment of Allan-Herndon-Dudley Syndrome.

3,4-Dimethoxybenzyl alcohol is a secondary metabolite of lignin-degrading fungi and is commonly used as a non-phenolic substrate to measure ligninolytic activity.Veratryl alcohol protects lignin peroxidase (LiP) from inactivation by H2O2 and prevents accumulation of LiP III compounds[3].

Dabigatran Etexilate Mesylate (BIBR 1048MS) is the orally active prodrug of dabigatran. Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI, Ki: 4.5 nM).

Atracurium besylate (51W89) is a non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.

Avatrombopag (YM477) is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation differentiation and platelet production.

Resveratrol (SRT 501) is a polyphenolic natural product, a plant antitoxin with antioxidant and chemopreventive activities. Resveratrol has a wide range of targets including COX, SIRT, LOC, etc. Resveratrol induces autophagy and apoptosis.

Rizatriptan benzoate (MK-462 Benzoate) selectively binds to and activates serotonin (5-HT) 1B receptors and 5-HT 1D receptors providing relief of migraine headaches.

Atropic acid (Acrylic acid) (Ipratropium EP Impurity D) is an impurity of Ipratropium bromide and Atropine Sulfate.

Sodium diatrizoate is an iodinated radiopaque X-ray contrast agent used as a diagnostic aid in angiography, urography, and radiography. It induces mitochondrial renewal and oxidative stress through calcium dysregulation and activates apoptosis.

Triacetylresveratrol (Acetyl-trans-resveratrol) has anti-cancer activity,it inhibits the phosphorylation of STAT3 and NFκB, down-regulates Mcl-1, and up-regulates Bim and Puma in pancreatic cancer cells.

Matrine (Vegard), an alkaloid isolated from the Sophora genus, acts as a kappa opioid receptor agonist.

Veratric acid (3,4-Dimethoxybenzoic acid) is a benzoic acid derivative from plants and fruits, possessing antioxidant, anti-inflammatory, and blood pressure-lowering properties.

Ipratropium Bromide (Sch 1000) is a synthetic anticholinergic agent that is used as an inhalant for treatment of acute bronchospasm due to chronic bronchitis and emphysema.

Atraric acid derivatives as a new chemical lead structure for novel therapeutic compounds as AR antagonists, that can be used for prophylaxis or treatment of prostatic diseases. It inhibits PTP1B activity in a dose-dependent manner with IC50 values of 51.5 uM, suggest that atraric acid has potential to treat diabetes.

Atrazine (Oleogesaprim) is an herbicide that does not occur naturally,and is a selective triazine herbicide. Atrazine (Oleogesaprim) is also a potent endocrine disruptor.

Ramatroban (BAY u3405) (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis. It has been used in trials studying the treatment of Asthma.

Cisatracurium besylate (51W89) is a nondepolarizing skeletal muscle relaxant intended for intravenous administration.

Sumatriptan succinate (GR 43175), a serotonin1 (5-HT1) receptor agonist, is used in the acute treatment of a migraine headache.